• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Companies that Ward Off ESG and Reputation Crises See Value Surge

    3/8/22 8:00:00 AM ET
    $APO
    $CVS
    $FB
    $JNJ
    Investment Managers
    Finance
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $APO alert in real time by email

    PITTSBURGH, March 8, 2022 /PRNewswire-PRWeb/ -- Companies with ESG and reputational risk protection strategies have seen their stock prices rise 5% above the market within two weeks of a reputational challenge, and that premium is almost double for companies that have publicly shared and validated those strategies.

    The study, by Steel City Re, an ESG and reputation insurer, also found that stock prices of firms that managed, validated and publicized ESG and reputation risk management strategies on average gained 9.3% over the subsequent seven months after a precipitating event, while firms in which such processes were in assumed by shareholders to be in place gained 4.3%. Companies that failed to institute, validate, and communicate risk management strategies lost 13.2% of their stock value over those seven-month periods, and they underperformed their peers by an average of 23.3%.

    "Investors appear to reward firms that actively manage reputational risks as operational strategies and not just potential PR problems," said Nir Kossovsky, Steel City Re's CEO. "Our study makes the case for ESG-focused firms to take a more structured, substantive and comprehensive approach to risk governance and management."

    "The data show that instituting, validating, and communicating risk management strategies can both fulfill the goals of stakeholder-centrism and meet shareholder expectations," he added.

    Illustrative highlights include:

    • Johnson & Johnson (NYSE:JNJ) outperformed the market by 16% ($1.7bn) when its much publicized strategic supply chain security and product safety processes were proven effective in 1986.
    • Rolls Royce (OTC:RYCEY), whose board defined its risk governance mission as protecting the reputation, viability, and profitability of the firm, outperformed the market by 14.9% ($3.4bn) after it proved the quality of its safety controls throughout its supply chain in 2011.
    • Apollo Global Management (NYSE:APO) outperformed the market by 16.6% ($1.9bn) after it announced an ESG-focused governance reorganization and presented in 2021 and independent validation of a 3-year investment in reputation risk management.
    • CVS (NYSE:CVS) outperformed the market by 9.3% ($8.6bn) when, presciently anticipating the ESG movement, it pursued an ethical innovative strategy that shunned tobacco products in 2014. It outperformed rivals Walgreens (NYSE:WBA) and Rite Aid (NYSE:RAD) by 16.6% and 24.8% respectively.
    • Apple (NADQ:AAPL) outperformed the market by 24% ($505bn) after introducing innovative ethical privacy features that addressed a critical ESG concern in the technology sector in 2021. It outperformed Meta (NYSE:FB), facing a range of privacy challenges, by 34.9%.

    About the Study

    The Steel Re study looked at seven firms that took direct action to publicize their reputation risk management and governance, 20 firms whose protection strategies were in assumed by shareholders to be in place because of their response to external events, 20 firms whose strategies were shown to be insufficient over seven months, and from among these, 22 firms whose reputational impairment and value losses were measured against peer competitors.

    The reputational challenges were all public events over the past 15 years supplemented by iconic cases of Johnson & Johnson's two Tylenol-related safety events of the 1980's. Individual gains and losses were calculated after normalizing for changes in the S&P500, and the date for ESG and reputational events was determined by a marked surge in stakeholder interest as explored in a related Steel City Re white paper.

    About Steel City Re

    Steel City Re provides parametric ESG insurance, reputational insurance and helps guide companies' boards and senior leadership in developing enhanced risk governance and management practices. Its underwriting model is supported by more than 7.3 million measures of reputational value and traditional financial metrics that also fuel ESG-focused hedge fund strategies. Its risk governance and management models are informed by principles of behavioral economics.

    Media Contact

    Desiree Niccoli, Steel City Re, 412-804-8649, desiree@alschulerpr.com

    Steve Alschuler, Steel City Re, 917-647-2151, steve@alschulerpr.com

     

    SOURCE Steel City Re

    Get the next $APO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APO
    $CVS
    $FB
    $JNJ

    CompanyDatePrice TargetRatingAnalyst
    Apollo Global Management Inc. (New)
    $APO
    7/20/2026$145.00Buy
    HSBC Securities
    Johnson & Johnson
    $JNJ
    5/13/2026$265.00Market Perform → Outperform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    4/8/2026$250.00Buy
    TD Cowen
    CVS Health Corporation
    $CVS
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    Apollo Global Management Inc. (New)
    $APO
    2/24/2026$142.00Sector Perform
    RBC Capital Mkts
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Apollo Global Management Inc. (New)
    $APO
    12/11/2025$186.00Buy
    UBS
    Apollo Global Management Inc. (New)
    $APO
    11/20/2025$180.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $APO
    $CVS
    $FB
    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global Corp Affairs Broadhurst Vanessa exercised 23,054 shares at a strike of $130.77 and sold $5,792,686 worth of shares (23,054 units at $251.27) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    7/21/26 5:27:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Cont & Chief Acct Officer Clark James David covered exercise/tax liability with 454 shares, decreasing direct ownership by 2% to 27,606 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/29/26 3:11:55 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    6/12/26 5:23:31 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pet medications now available at CVS Pharmacy®

    Dog and cat owners can now fill common pet prescriptions at all CVS Pharmacy locations nationwideWOONSOCKET, R.I., July 21, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that common prescription medications for dogs and cats are now available at its approximately 9,000 CVS Pharmacy® locations nationwide. Pet owners can fill prescriptions for select pet-only medications, including antibiotics, allergy, flea and tick control, insulin, and pain relievers, at their local CVS Pharmacy, expanding access to essential pet health care. Greater flexibility in where pet prescriptions are filled helps reduce stress and delays, ensuring pets receive the medications they need conveniently w

    7/21/26 9:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

    Issued on behalf of Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP)NEW YORK and TORONTO, July 21, 2026 /CNW/ -- USA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. Tens of millions of adults live with major depressive disorder, and the majority never reach full remission on the first medication they try. That persistent treatment gap has drawn a wave of biotech and pharmaceutical companies into what is now one of the most closely watched races in interventional psychiatry, each pursuing a different way to reach patients that current antidepressants leave behind.

    7/21/26 9:00:00 AM ET
    $CMPS
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

    Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations Transform Patient CareNEW YORK, July 21, 2026 /CNW/ -- Market News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in patient outcomes due to new approaches introduced by pharmaceutical companies. Traditionally, treatments focused on boosting serotonin levels or other neurotransmitters, resulting in long waiting periods for patients to notice any changes, without any assurance of effectiveness. However, there is now a shift towards quicker-acting medications, exploration of new biological targets, and the development of perso

    7/21/26 8:30:00 AM ET
    $ATAI
    $CMPS
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    SEC Filings

    View All

    Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    7/15/26 7:49:04 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Johnson & Johnson

    11-K - JOHNSON & JOHNSON (0000200406) (Filer)

    6/25/26 5:15:53 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 11-K filed by Johnson & Johnson

    11-K - JOHNSON & JOHNSON (0000200406) (Filer)

    6/25/26 5:13:18 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HSBC Securities initiated coverage on Apollo Global Management with a new price target

    HSBC Securities initiated coverage of Apollo Global Management with a rating of Buy and set a new price target of $145.00

    7/20/26 8:55:10 AM ET
    $APO
    Investment Managers
    Finance

    Johnson & Johnson upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00

    5/13/26 7:59:34 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Financials

    Live finance-specific insights

    View All

    Altius Reports Q2 2026 Expected Record Attributable Revenue(1)

    All references in thousands of Canadian dollars, except per share amounts, unless otherwise indicated Altius Minerals Corporation (ALS: TSX) (ATUSF: OTCQX) ("Altius" or the "Corporation") expects to report Q2 2026 record attributable royalty revenue(1) of approximately $30.0 million compared to $12.7 million in Q2 2025. Royalty Revenue Summary Summary of attributable royalty revenue(1) Q2 2026 Q1 2026 Q2 2025 Base metals $ 9,425 $ 9,103 $ 4,633 Potash   5,036   4,507   4,115 Lithium   6,434   5,429   61 Iron ore#

    7/20/26 7:45:00 AM ET
    $APO
    Investment Managers
    Finance

    DePuy Synthes Acquires Expanding Innovations™

    Transaction will bring expandable interbody cage solutions to DePuy Synthes' Spine portfolio to strengthen position across the lumbar fusion market DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment. Expanding Innovations (EI) is a commercial-stage medical technology company focused on developing and commercializing expandable implant technologies for spine surgery. Their proprietary, non-screw-b

    7/16/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

    7/15/26 6:25:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    Athene Names Larik Hall as Senior Vice President, Head of Athene Japan

    WEST DES MOINES, Iowa, June 30, 2026 (GLOBE NEWSWIRE) -- Athene, the leading retirement solutions company and subsidiary of Apollo Global Management, Inc. (NYSE:APO), today announced that Larik Hall has joined the company as Senior Vice President and Head of Japan. Hall will be based in Japan and will oversee Athene’s growth strategy to accelerate the expansion of retirement solutions offered in the country. "Japan is one of the most important retirement markets globally, shaped by an aging demographic, a growing need for long-term retirement security and a new economic regime that has demanded a new playbook," said Grant Kvalheim, CEO of Athene. "Larik’s strong track record of building r

    6/30/26 7:00:00 PM ET
    $ATH
    $APO
    Life Insurance
    Finance
    Investment Managers

    Apollo Adds Senior Policy and Government Affairs Leaders in Europe

    Huw van Steenis to Join as European Economic & Policy Strategist Sarah Jenkins to Join as Head of Government Affairs, Europe LONDON and NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE:APO) today announced that Huw van Steenis will join the firm as a Partner and European Economic & Policy Strategist, and that Sarah Jenkins will join the firm as a Managing Director and Head of Government Affairs for Europe. Both newly created positions start in August and are based in London, Apollo's European headquarters. Van Steenis has spent more than 25 years in leadership and senior advisory roles for global financial institutions, with a focus on strategy, policy and economic research. He

    6/10/26 1:00:00 AM ET
    $APO
    Investment Managers
    Finance

    Stream Data Centers' Executive Leadership Expands to Meet Accelerated Hyperscale Demand, Deliver Efficient, Capital-Backed Results

    New Chief Financial Officer and Executive Vice President of Construction Empower Trusted Leasing and Delivery Strategies Built for Evolving Customer Requirements Stream Data Centers, a time-tested hyperscale partner and one of the longest-standing developers in the industry, announces two new additions to its leadership team: Murray Woolcock, Chief Financial Officer, and Scott Greubel, Executive Vice President, Construction. Offering more than 50 years of combined experience, Woolcock and Greubel empower Stream's growth to meet hyperscale customer requirements with reliable, configurable, and scalable deal structures and construction strategies. "The fact that both Murray and Scott be

    5/14/26 9:03:00 AM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples